OBI Pharma

OBI Pharma is a healthcare company dedicated to addressing unmet medical needs in challenging diseases, primarily focusing on cancer and infectious diseases. The company emphasizes improving health and quality of life through innovative and cost-effective therapeutics. OBI Pharma's core expertise lies in research and development, particularly in creating novel therapies for cancer and infectious diseases, utilizing its proprietary OPopS™ drug discovery platform to enhance its product pipeline. The company's leading candidate is OBI-822, an active immunotherapy for metastatic breast cancer currently undergoing a multinational Phase 2/3 clinical trial. Additionally, OBI Pharma is committed to developing next-generation immunotherapies for various difficult-to-treat cancers, including lung, prostate, pancreatic, stomach, and ovarian cancers. The company also holds the commercial rights to DIFICID™, a novel antibiotic for C. difficile-associated diarrhea. With wholly-owned subsidiaries in the US and China, OBI Pharma is backed by a management team experienced in drug development and commercialization.